1. Grönberg H.
Prostate cancer epidemiology.
Lancet 2003 8;361:859-64.
2.Lemaitre L,
Rouvière O,
Penna-Renard R,
Villers A,
Puech P.
MRI and prostate cancer: a paradigm shift,
J Radiol 2008;89:1053-63.
3.
Barentsz JO,
Richenberg J,
Clements R,
Choyke P,
Verma S,
Villeirs G,
Rouviere O,
Lagager V,
Fütterer JJ.
ESUR prostate MR guidelines 2012.
Eur Radiol 2012 ;22 :746-57.
4.
Somford DM,
Hambrock T,
Hulsbergen-van de Kaa CA,
Fütterer JJ,
van Oort IM,
van Basten JP,
Karthaus HF,
Witjes JA,
Barentsz JO.
Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol 2012;47:153-8.
5.
Vargas HA,
Akin O,
Franiel T,
Mazaheri Y,
Zheng J,
Moskowitz C,
Udo K,
Eastham J,
Hricak H.
Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011;259:775-84.
6.
Tamada T,
Sone T,
Higashi H,
Jo Y,
Yamamoto A,
Kanki A,
Ito K.
Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging,
dynamic contrast-enhanced MRI,
and T2-weighted imaging. AJR Am J Roentgenol 2011;197:664-70.
7.
Katahira K,
Takahara T,
Kwee TC,
Oda S,
Suzuki Y,
Morishita S,
Kitani K,
Hamada Y,
Kitaoka M,
Yamashita Y.
Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol 2011;21:188-96.